Acquired dPCR Combinati was acquired by Thermo Fisher Scientific in 2021, indicating a strategic value in digital PCR technology and potential alignment with Thermo Fisher customer bases and distribution channels for selling complementary or upgraded dPCR solutions.

Strategic Opportunity Post acquisition, there may be opportunities to position enhanced digital PCR capabilities to Thermo Fisher customers or integrate with Thermo Fisher platforms, offering bundle deals or migration paths for labs seeking scalable, validated dPCR workflows.

Low Footprint With a reported small team and location in Palo Alto, Combinati’s niche offering could benefit from enterprise partnerships, OEM arrangements, or channel programs to accelerate market reach without heavy internal expansion.

Democratized dPCR The product promise of simplicity, robustness and minimal waste positions it well for labs transitioning from qPCR or those needing precise longitudinal biomarker tracking, suggesting opportunities in mid-market research accounts and contract research organizations.

Funding Signals Revenue is minimal and the platform emphasizes accuracy and adoption; sales conversations can leverage case studies or pilot programs demonstrating ROI, cost-per- assay reductions, and improved data quality to drive adoption among target life sciences buyers.